Fig. 3: DLGAP5 knockdown synergizes with DCT in an androgen-dependent manner. | Cell Death & Disease

Fig. 3: DLGAP5 knockdown synergizes with DCT in an androgen-dependent manner.

From: A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor

Fig. 3

a Incucyte growth assay: Growth was measured as area of confluency. Curves show growth inhibition of DCT treatment relative to DMSO, for two doses of DCT. Shown is mean of experiments + SEM (n = 3). DLGAP5 knockdown (pool of three siRNAs, blue curves) synergizes with DCT in this assay. The effect is attenuated by additional AR knockdown (pool of four siRNAs, yellow curves). Significance was calculated by comparing AUC followed by T-test (shown for 1.0 nM condition, right hand side). *p < 0.05, **p < 0.01. b Toxicity assay with CytoxGreen shows a similar attenuation under AR knockdown. c Dose response curves at 48 h drug exposure. d Dose response curves in androgen desensitized LNCaP-AI cells. In doses up to 4 nM DCT there is no significant effect of DLGAP5. e Dose response curves in parental LNCaP cells that were exposed to androgen inhibition by enzalutamide for 1 h prior to DCT exposure show no attenuation. f, g Western blots for DLGAP5 and AR protein confirm the knockdown effect of the siRNA pools, and show no significant difference of DLGAP5 and AR protein under AR and DLGAP5 knockdown, respectively

Back to article page